The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Cidara Therapeutics | Common Stock | 171757107 | 3,604 | 444,965 | SH | SOLE | 444,965 | 0 | 0 | ||
CymaBay Therapeutics | Common Stock | 23257D103 | 4,445 | 551,477 | SH | SOLE | 551,477 | 0 | 0 | ||
Dicerna Pharmaceuticals | Common Stock | 253031108 | 1,285 | 223,457 | SH | SOLE | 223,457 | 0 | 0 | ||
Egalet | Common Stock | 28226B104 | 3,699 | 2,889,926 | SH | SOLE | 2,889,926 | 0 | 0 | ||
ESSA Pharma | Common Stock | 29668H104 | 492 | 1,696,969 | SH | SOLE | 1,696,969 | 0 | 0 | ||
FibroGen | Common Stock | 31572Q808 | 16,912 | 314,348 | SH | SOLE | 314,348 | 0 | 0 | ||
Jounce Therapeutics | Common Stock | 481116101 | 9,031 | 579,650 | SH | SOLE | 579,650 | 0 | 0 | ||
Juno Therapeutics | Common Stock | 48205A109 | 48,207 | 1,074,612 | SH | SOLE | 1,074,612 | 0 | 0 | ||
Paratek Pharmaceuticals | Common Stock | 699374302 | 65,270 | 2,600,410 | SH | SOLE | 2,600,410 | 0 | 0 | ||
Pieris Pharmaceuticals | Common Stock | 720795103 | 6,935 | 1,204,053 | SH | SOLE | 1,204,053 | 0 | 0 | ||
Sienna Biopharmaceuticals | Common Stock | 82622H108 | 16,879 | 758,610 | SH | SOLE | 758,610 | 0 | 0 |